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in managing the characteristically slow hematologic recovery
after CBT, a large comparative study of CBT versus TCD PBSCT
might well reveal a signiﬁcant outcome beneﬁt for the richer
stem cell product. Together with the intrinsic opportunities
conferred by PBSCT of a continuing source of lymphocytes
and stem cells to treat disease relapse and BM failure, such
a study could swing the balance away from CBT in favor of
TCD PBSCT. We live in a time of rapid advances, however; by
the time such a clinical trial is conceived and implemented,
related haploidentical SCT may emerge as a key contender to
be evaluated against unrelated donor SCT [4].
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Accepted 9 September 2013High-dose melphalan followed by autologous hemato-
poietic stem cell transplantation (auto-HSCT) remains an
integral component of the treatment of transplantation-
eligible patients with multiple myeloma (MM). This treat-
ment is technically not a transplantation, but rather is
a rescue from the marrow-toxic effects of melphalan using
the patient’s own hematopoietic stem cells (HSCs); however,
the term “transplantation” is widely used to describe this
treatment, and so is used herein.
Melphalan has been dose-intensiﬁed to treat plasma cell
leukemia and MM [1], but this therapy is limited by pro-
longed pancytopenia at higher doses of melphalan. Barlogie
et al. [2] initially demonstrated the utility of auto-HSCT with
bone marrow (BM) grafts, leading to the broad application
of auto-HSCT as part of the continuum of initial or later
treatment of transplantation-eligible patients with MM. The
ﬁrst use of mobilized peripheral blood (PB) as a stem cell
source was reported in 1989 [3] and has led to the use of
growth factor (with or without chemotherapy)emobilized
PB as a stem cell source, usually after a high-dosemelphalan-based regimen. A phase III study demon-
strating the superiority of auto-HSCT over chemotherapy
had led to the widespread use of auto-HSCT as part of the
initial therapy for transplantation-eligible patients with MM
[4]. Terms for the autologous HSCs used for rescue/trans-
plantation include BM, blood or marrow (allowing for the
continued use of BM as an abbreviation), PB, HSCs, and
hematopoietic progenitor cells (HPCs).
The study of Costa et al. [5] reported in this issue of
Biology of Blood and Marrow Transplantation demonstrates
the increased use of auto-HSCT as part of the initial therapy
for transplantation-eligible patients with MM from 1995 to
2010. The study population comprised 20278 patients with
MM, 11644 of whom underwent auto-HSCT between 2005
and 2010. Given the formidable challenge of collecting
complete data from more than 20000 patients, the investi-
gators conducted a detailed analysis of a subset of 4373
patients with more detailed information. This study further
limited eligibility to patients who were within 1 year of MM
diagnosis, thus reﬂecting early and possibly more aggressive
disease. This eligibility criterion did not capture those
smoldering patients with MM requiring therapy more than 1
year after the initial diagnosis. The cohort likely reﬂects the
majority of symptomatic transplantation-eligible patients
withMM, but this is uncertain, owing to the large percentage
of patients without Durie-Salmon and International Staging
System scores at diagnosis (49% and 39%, respectively).
Factors that have changed over time include the increasing
use of auto-HSCT in patients aged 65 years, the abandon-
ment of most nonemelphalan-containing regimens in favor
of single-agent melphalan regimens, the increased use of
planned tandem auto-HSCT, and the increased use of
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domide) and the proteasome inhibitor (PI) bortezomib
during induction, likely resulting in a higher percentage of
patients with MM undergoing transplantation while in
complete remission (CR) or partial remission (PR).
One important point is the deﬁnition of “transplantation
eligible.” Based on the increasing numbers of patients over
age 65 who undergo auto-HSCT, it would be reasonable to
consider performance status and comorbidities as factors
deﬁning transplantation eligibility rather than age. Other
factors not included in the analysis are cytogenetic testing,
especially by ﬂuorescent in situ hybridization, to stratify risk;
the categorization of responses as PR, very good PR, and CR
instead of grouping PR and CR together; the lack of clear
detail as to the use of doublets ( [PI] and steroids or IMiD and
steroids) or triplets (IMiD, PI, and steroids or IMiD or PI with
steroids and an alkylating agent), and the use of molecular or
ﬂow cytometry testing to determine the presence or absence
of minimal residual disease.
The majority of patients in the Costa study had minimal
exposure to plerixafor, which is more commonly used to
mobilize HSCs. IMiDmaintenance therapywas used in 20% of
the patients in 2005-2010, reﬂecting the problemwith long-
term tolerability of thalidomide and the fact that no lenali-
domide maintenance studies were published until 2012.
Finally, the limited number of patients evaluated in 2009 and
2010 reﬂects the lag time in reporting to the Center for
International Blood and Marrow Transplantation research
(CIBMTR), which improves over time. This study clearly
shows improved progression-free survival (PFS) and overall
survival (OS), as well as in survival after relapse/progression,
conﬁrming a previous study of a CIBMTR cohort including
patients with MM undergoing auto-HSCT both early and late
after diagnosis [6]. Nonetheless, patients continue to expe-
rience disease progression and succumb to MM over time.
Thus, such strategies as consolidation and maintenance
therapy have been developed to prolong response and
prevent progression, with the goal of improved survival.
Lenalidomide and bortezomib are the latest agents that have
been shown to improve PFS and, in some cases, OS [7]. A
future CIBMTR analysis should reﬂect how these strategies
will control disease and improve survival.
WHERE ARE WE GOING?
Several large phase III trials examining different
approaches to the treatment of MM have been completed
and are awaiting longer follow-up or are currently accruing
patients for determining optimal treatment strategies. Two
phase III trials examining chemotherapy versus upfront
tandem auto-HSCT have shown improved PFS with tandem
auto-HSCT, with no difference in OS [8,9]. One of these
studies [8] demonstrated a PFS beneﬁt and a possible OS
beneﬁt from lenalidomide maintenance, whereas the other
[9] randomized patients to lenalidomide and prednisone
versus lenalidomide maintenance. Neither trial included a PI
in therapy, and both trials await longer-term follow-up. Two
ongoing studies [10,11] are examining upfront versus
delayed auto-HSCT and may identify those patient pop-
ulations that should undergo early auto-HSCT and those in
whom auto-HSCT can be deferred to ﬁrst progression. The
Dana Farber Cancer Institute/Intergroupe Francophone du
Myelome trial is examining early versus late auto-HSCT after
upfront induction therapy [10]. The duration of lenalidomide
maintenance is 1 year in Europe and until progression isnoted in the US. This nonrandomized allocation may allow
for comparison of PFS and OS with the 2 approaches. The
European Myeloma Network is evaluating chemotherapy
versus single auto-HSCT versus tandem auto-HSCT [11]. All
arms are randomized to lenalidomide maintenance or
consolidation, followed by lenalidomide maintenance. The
BMT-CTN 0702 trial [12] is examining single auto-HSCT after
3 different treatments: second transplantation, lenalido-
mide, bortezomib and dexamethasone consolidation, or no
further intensive therapy. All patients receive 3 years of
lenalidomide maintenance therapy. These trials will help
deﬁne optimal approaches to the long-term control of MM,
including tandem auto-HSCT, consolidation, and duration of
maintenance.
The newly approved agents carﬁlzomib and pomalido-
mide may be incorporated earlier in the treatment of
patients with newly diagnosedMM. Several classes of agents,
including oral proteasome inhibitors, deacetylase inhibitors,
monoclonal antibodies, kinase inhibitors, and heat shock
protein inhibitors, have demonstrated activity against MM
[13]. Thus, we are in a golden age of therapy for MM, with
auto-HSCT remaining an important component of the ther-
apeutic approach for transplantation-eligible patients.
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